Results 21 to 30 of about 1,819,904 (233)
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +7 more sources
Stent thrombosis and drug-eluting stents [PDF]
Journal of Cardiology, 2011 Coronary stents have been used for the treatment of patients with coronary artery disease (CAD), and significantly improved procedural safety and are associated with a lower rate of restenosis compared with balloon angioplasty alone. Drug-eluting stents (DES) have been dominant for the treatment of CAD with efficacy in significantly reducing both ...
Takayama, Tadateru +2 more
openaire +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Premature discontinuation of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is related to higher short‐term risks of adverse outcomes. Whether these risks persist in the long‐term is uncertain. Methods and Results We
Scott Kinlay +11 more
doaj +1 more source
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. [PDF]
, 2007 BACKGROUND: The safety of drug-eluting stents has been called into question by recent reports of increased stent thrombosis, myocardial infarction, and death.
Kirtane, Ajay J +14 more
core +1 more source
The role of optical coherence tomography guidance in scaffold versus stent optimization
The Egyptian Heart Journal, 2020 Background Optical coherence tomography showed a great ability to identify adverse features during percutaneous coronary intervention with drug-eluting stents and resulted in better clinical outcomes.
Arif A. Al Nooryani +4 more
doaj +1 more source
The future of drug eluting stents [PDF]
Heart, 2005 In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10–40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation.
Anis, RR, Karsch, KR
openaire +3 more sources
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. [PDF]
, 2009 BACKGROUND: There is no consensus regarding the safety and efficacy of drug-eluting stents, as compared with bare-metal stents, in patients with ST-segment elevation myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI)
Brodie, Bruce R. +23 more
core +1 more source
An Analysis of Cost-Effectiveness of Stents Used in the Treatment of Coronary Artery Disease
Balkan Medical Journal, 2019 Background: There is only limited information about the cost-effectiveness of drug-eluting stents compared with bare-metal stents in Turkey. Aims: To evaluate bare-metal and drug-eluting stents used in the treatment of coronary artery disease from the ...
Ferda Işıkçelik +2 more
doaj +1 more source
Coronary Artery Disease, 2019 Approximately, 10-20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal management of recurrent DES-ISR is unknown. We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting balloons (DEB) to those with repeated implantation of new-generation DES.A total of 172 ...
Wang, Guozhong +5 more
openaire +3 more sources
Drug Distribution and Stent Retention of Drug Eluting Stents [PDF]
, 2008 In this paper the examinations of drug eluting coronary stents are shown, such as the morphology of the coatings before expansion, drug distribution, the methodology and the value of stent retention.
Dobránszky, János +3 more
core +1 more source